These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30532022)

  • 1. A promising outlook for diabetic kidney disease.
    Cooper M; Warren AM
    Nat Rev Nephrol; 2019 Feb; 15(2):68-70. PubMed ID: 30532022
    [No Abstract]   [Full Text] [Related]  

  • 2. SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    Shaughnessy AF
    Am Fam Physician; 2021 Aug; 104(2):206. PubMed ID: 34383432
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dulaglutide and liraglutide compared].
    Bruhn C
    Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
    [No Abstract]   [Full Text] [Related]  

  • 4. New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
    Hussar DA; Wetty DR
    J Am Pharm Assoc (2003); 2015; 55(1):106, 108-10. PubMed ID: 25575154
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypothalamic obesity after craniopharyngioma surgery: Treatment with a long acting glucagon like peptide 1 derivated.
    Castro-Dufourny I; Carrasco R; Pascual JM
    Endocrinol Diabetes Nutr; 2017 Mar; 64(3):182-184. PubMed ID: 28440760
    [No Abstract]   [Full Text] [Related]  

  • 6. Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.
    Vinagre I; Gerstein H; Viñals C; Conget I
    Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):467-468. PubMed ID: 30890422
    [No Abstract]   [Full Text] [Related]  

  • 7. Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.
    Edelman SV
    J Fam Pract; 2017 Oct; 66(10 Suppl):S12-S16. PubMed ID: 28991932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.
    Tuttle KR; McKinney TD; Davidson JA; Anglin G; Harper KD; Botros FT
    Diabetes Obes Metab; 2017 Mar; 19(3):436-441. PubMed ID: 27766728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis.
    Ferrannini G; Mellbin LG; Kirabo F; Ramasundarahettige C; Gerstein HC; Rydén L
    Diabetes Care; 2022 Oct; 45(10):e146-e147. PubMed ID: 36040063
    [No Abstract]   [Full Text] [Related]  

  • 10. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
    Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Botros FT; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
    Lancet; 2019 Jul; 394(10193):131-138. PubMed ID: 31189509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease.
    Tuttle KR; Cherney DZ;
    Clin J Am Soc Nephrol; 2020 Feb; 15(2):285-288. PubMed ID: 31740570
    [No Abstract]   [Full Text] [Related]  

  • 13. Two new GLP-1 receptor agonists for diabetes.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):109-11. PubMed ID: 25372847
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months.
    Moreno Obregón F; Miramontes-González JP; Romo Guajardo-Fajardo C; Nieto-Sánchez Á; López-Suárez JM; Martín-Vallejo J; Arco-Prados Y; Dolores García de Lucas M; León-Jiménez D
    Diabetes Res Clin Pract; 2019 Dec; 158():107916. PubMed ID: 31682882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Rev Clin Pharmacol; 2016; 9(3):385-99. PubMed ID: 26761217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic kidney disease in 2017: A new era in therapeutics for diabetic kidney disease.
    Wanner C
    Nat Rev Nephrol; 2018 Feb; 14(2):78-80. PubMed ID: 29307892
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
    Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
    Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis.
    Yajima T; Yajima K; Takahashi H; Yasuda K
    J Diabetes Complications; 2018 Aug; 32(8):759-763. PubMed ID: 29937137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dulaglutide: A Review in Type 2 Diabetes.
    Scott LJ
    Drugs; 2020 Feb; 80(2):197-208. PubMed ID: 32002850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.
    Terauchi Y; Satoi Y; Takeuchi M; Imaoka T
    Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.